anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Normal sleep condition in the first period and sleep restriction condition in the second period. Each period will consist of a 10-day inpatient visit comprising a 3-day/2-night baseline, followed by a 5-day/5-night experimental phase, and a 2-day/2-night recovery phase.
In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
FIELD: medicine. SUBSTANCE: method involves forming healthy life style norms and oral cavity and maxillofacial area organs health at the early stage of value orientation development. The process is continued later in taking under consideration age, psychological and functional abilities of the trainees. The training is started beginning from the age of 3 years. Collective lessons with games are given to children in pre-school institutions in the amount of 10 lessons of 15 min duration. The education process is continued in primary school at the age of 6-7 years in the field of sanitary education and practical measures in popular form. The education is continued in middle school age groups aged 10-14 years and finished in senior school age groups of 15-17 years old children in giving lessons with scientific approach based on developing esthetic feelings of girls and boys. The number and duration of lessons differentiated in each age group and their qualitative features are shown. EFFECT: achieved healthy person development independently of social standard and family wealth level.
PURPOSE OF REVIEW: This article offers an overview of recent randomized controlled trials (RCTs) testing the efficacy of veno-arterial extracorporeal membrane oxygenation (VA ECMO) and microaxial flow pump (mAFP) in treating cardiogenic shock, including findings from the DanGer shock trial. It summarizes the clinical implications and limitations of these studies and key decision-making considerations for cardiogenic shock device use.
RECENT FINDINGS: Despite important limitations in all published RCTs, the routine use of VA ECMO for acute myocardial infarction related cardiogenic shock did not demonstrate benefit and should be reserved for selected patients with extreme forms of cardiogenic shock. Conversely, mAFP (Impella CP) appears promising for cardiogenic shock due to ST elevation myocardial infarction. A stepwise approach - initial mAFP use for cardiogenic shock with left ventricular failure, supplemented by VA ECMO if mAFP is inadequate or if severe right ventricular failure is present - may be preferable, but requires validation through RCTs. High complication rates in device arms underscore the need for careful patient selection, preventive strategies, education for centers and operators, and further research.
SUMMARY: Recent trials offer insights into mechanical circulatory support in cardiogenic shock, but their real-world applicability is limited. Despite potential benefits, the use of VA ECMO and mAFP is associated with significant complication rates, emphasizing the need for personalized use.
The patients were instructed to do as an home exercise program in first 2 weeks, 5 s contraction and 10 s relaxation, including two sets of 5 repetition daily, in following 2 weeks 10 s contraction and 20 s relaxation, including two sets of 10 repetition daily, and after 4 weeks, 10 s contraction and 20 s relaxation including three sets of 10 repetition daily in three different position (lying, sitting, and standing). So in the first 2 weeks 30 contractions daily, in following 2 weeks 60 contractions daily and upward 4th weeks, 90 contractions daily with progressively increasing intensity was done. All patients were asked to mark the exercise at a daily home schedule. Patients who did not complete more than 20% of the list according to the daily home program were excluded from the study.
If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. Lidotral™ (Lidocaine HCl) 3.88% Cream should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of lidocaine.

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic potential of the effect on fertility have not been conducted.

Use in Pregnancy: Teratogenic Effects; Pregnancy Category B. Reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this drug is administered to a nursing mother.

Pediatric Use: Dosage in pediatric patients would be reduced commensurate with age, body weight and physical condition.
Background: Despite the extensive literature on facilitating advance care planning (ACP) with patients with serious illnesses, opportunities to include surrogates or family caregivers are overlooked. The research objective was to examine whether previous medical decision-making involvement for a loved one is associated with one's own ACP conversations with family and the potential mediating effect of knowledge of a loved one's end-of-life treatment preferences. Methods: This study employed a cross-sectional design using data from the 2016 Kaiser Family Foundation/The Economist Four-Country Survey on Aging and End-of-Life Medical Care. The sample included 627 US adults who completed the survey and were involved in making medical decisions for a loved one in the past. Multiple binary logistic regression and linear regression models were established for mediation analyses. Results: Participants in our nationally derived sample were largely confident in their knowledge of a deceased loved one's end-of-life treatment preferences. 66.8% of the sample had ACP conversations with family. The involvement in a loved one's medical decision making was significantly associated with higher odds of having ACP conversations with family (OR = 1.93, P = .01), but this relationship was significantly mediated by knowledge of one's end-of-life treatment preferences (b = .31, Boot CI = .12-.49). Conclusions: Previous experience in making medical decisions for a loved one may facilitate one's own ACP behavior through knowing a loved one's end-of-life treatment preferences. Clinicians in end-of-life settings are uniquely positioned to engage family members who were involved in medical decision-making for others before in ACP.
Fractures in which bone has been exposed to the outside world through an associated skin injury, known as open fractures, are frequently encountered in orthopaedics. Traditionally, treatment calls for a formal, operative treatment in which the bone is exposed, foreign tissue is debrided and the wound is irrigated. The bone itself, depending on the age of the patient, fracture location and stability is then treated by the appropriate method of casting or internal fixation. However, while this is the current standard of care for all open fractures, not all open fractures are the same and can differ in terms of the bone involved, energy causing the injury and the skeletal maturity of the patient. Children, for example, have a thick periosteum which may diminish the rate of infection and decrease the time to healing. In addition, the protocol of operative debridement was introduced at the same time as widespread antibiotic use. It is not known whether the mechanical operative management or antibiotic use has resulted in improved outcomes. In retrospective studies, centers are reporting emergency department management alone may result in equal results without the time and expense of the operative theater.

The investigators propose a prospective, randomized trial of children with type I open fractures to evaluate whether formal operative treatment is necessary. The investigators hypothesize that minor open fractures in children can be safely treated in the emergency room with irrigation, closed reduction and home antibiotics without an increased risk of infection or other complications. If the inclusion criteria is met and informed consent is obtained, children will be randomized into two treatment arms - formal operative management (OR) and emergency department (ED) management. Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management. Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics. Both wounds will be examined at interval follow up periods for signs of infection. Outcomes evaluated will include the rate of infection, the number of return visits to the operating room, the time to bone healing, and other complications. This is a pilot study with the plan of eventually being a multicenter study evaluating open fracture care in children.
The invention relates to the field of daily chemical articles, in particular to a composition and facial mask liquid containing the composition. The facial mask liquid provided by the invention has good skin tendering and softening effects, and can brighten dull and uneven skin color. The face-beautifying cream is characterized by having a timely brightening effect, and being capable of restoring the natural and bright state of skin after long-term use, so as to achieve the white, red and healthy skin color. The whitening combination components adopted in the formula are safe and effective, do not contain prohibited raw materials such as hormone and the like, and the used antiseptic raw materials are not in an antiseptic list, have an antiseptic effect and have low irritation to skin, so the facial mask has the efficacy and can be used for a long time. In addition, the water and oil content of the skin of a subject is obviously changed after the mask prepared by the invention is used, the oil content is reduced, and the water content is increased. The product of the invention has better regulation and control capability on the moisture and oil content of the skin, can improve the skin oil environment, achieves good oil control effect, and enables the skin to be fresh and clean.
Obesity is a well-established risk factor for human cancer, yet the underlying mechanisms remain elusive. Immune dysfunction is commonly associated with obesity but whether compromised immune surveillance contributes to cancer susceptibility in individuals with obesity is unclear. Here we use a mouse model of diet-induced obesity to investigate tumor-infiltrating CD8 + T cell responses in lean, obese, and previously obese hosts that lost weight through either dietary restriction or treatment with semaglutide. While both strategies reduce body mass, only dietary intervention restores T cell function and improves responses to immunotherapy. In mice exposed to a chemical carcinogen, obesity-related immune dysfunction leads to higher incidence of sarcoma development. However, impaired immunoediting in the obese environment enhances tumor immunogenicity, making the malignancies highly sensitive to immunotherapy. These findings offer insight into the complex interplay between obesity, immunity and cancer, and provide explanation for the obesity paradox observed in clinical immunotherapy settings.
The invention relates to the technical field of cells, in particular to a composition and an application thereof. The composition comprises an umbilical cord stem cell exosome and a hepatocyte-like cell. The composition adopts the unit of the umbilical cord stem cell exosome and the hepatocyte-like cell to conduct tissue local injection, thus loss of exosome caused by hemokinesis can be avoided. The exosome can repair a damaged tissue directly, strengthen a resistant ability of an undamaged tissue, and shorten sharply repairing time of the tissue. The exosome preparation does not have immunogenicity, thus can be applicable to any individual. The hepatocyte-like cell can shorten adaptation of the tissue, perform functions directly under a microenvironment, and shorten cure period. The application of the exosome is safer compared with an direct application of the hepatocyte-like cell, and a method of non-cell therapy can be used. The exosome can be stored for a long time after being extracted, and is more convenient in preparation preparing during the application. Operations such as culturing cells again in a cell therapeutic scheme are avoided. By using the hepatocyte-like cell, the disadvantage of uncertainty of stem cell differentiation can be avoided.
The Laughie is a self created app or tool. It is a one minute recording of the user's joyful laughter on their smartphone. Once recorded, the user uses it by playing back the recording and laughing with it for the duration of the one minute. The Laughie acts as a prompt to guide the one minute of laughter.

In this research the experimental group each record their own Laughie, demonstrated and supported by the PI(s). They are then prescribed to laugh with their Laughie: 3x a day the first week (morning, lunch, and afternoon) and at least 2x a day during the second week. Immediately after using their Laughie they fill in a Laughie checklist to record whether they laughed for the full minute, whether they enjoyed their Laughie, and how they felt afterwards.

This study tracks sleep using wrist actigraphy in the control group (no Laughie prescription) and in the Laughie group. All participants complete one week baseline using sleep watches, and sleep diaries, prior to the Laughie intervention. They all then continue to track their sleep during the intervention. All participants complete WHO Five well-being, PSKI, and HADS pre and post intervention. During the intervention the Laughie participants complete Laughie checklists. All participants are invited for a final interview (the control group about the sleep equipment experience). A follow-up survey is sent to the Laughie group 2 months after their prescription.
Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
Intervention: daily baths with placebo wipes, oral spray and standard shampoo. This arm will receive wipes with the same components as arm #1 plus an oral spray application with the same components except chlorhexidine. For scalp, a standard shampoo will be used. These products will have the same labels and smell as the products in arm #1.
The calculation of the sample size was conducted with the statistical software G-Power 3.1 applying the chi-square homogeneity test. Identical sample sizes were considered for the aPDT group and the sham group. The percentage of type error was set at 5% and the statistical power at 80%, obtaining n = 30 considering 10% losses. The distribution of data within each group and the homogeneity of the variants will be verified for the choice of an analysis of variance or not. With this information the most proper statistical test will be conducted. The sample size calculation is based on the literature and a 5% significance level will be adopted
Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Sorafenib starting dose: 200 mg by mouth daily for 28 a day cycle.
INTRODUCTION: Acute pancreatitis is one of the main reasons for digestive admissions. Adequate pain treatment is crucial in its management. However, there are hardly any descriptions of the analgesic guidelines used in our setting.
METHODS: On-line survey on analgesic management in acute pancreatitis, aimed at attending physicians and residents practising in Spain.
RESULTS: Two hundred and nine physicians from 88 centres responded to the survey. Ninety percent were specialists in gastrointestinal medicine and 69% worked in a tertiary centre. The majority (64.4%) do not routinely use scales to measure pain. When choosing a drug, experience in its use was the most important factor. The most commonly prescribed initial treatments are: combination of paracetamol and metamizole (53.5%), paracetamol alone (19.1%) and metamizole alone (17.4%). As rescue: meperidine (54.8%), tramadol (17.8%), morphine chloride (17.8%) and metamizole (11.5%). Continuous perfusion is used in 8.2% of initial treatments. Physicians with >10 years of service use more metamizole as monotherapy (50%), while residents and attending physicians with <10 years of service prescribe it in combination with paracetamol (85%). If progression is needed, morphine chloride and meperidine are mainly used. The speciality of the respondent, the size of the work centre and the unit/service where the patients were admitted did not influence the analgesia prescribed. Satisfaction with pain management reached 7.8/10 (SD 0.98).
CONCLUSION: In our setting, metamizole and paracetamol are the most commonly used analgesics as initial pain treatment in acute pancreatitis, and meperidine is the most commonly used rescue analgesic.
PURPOSE:To obtain the titled food capable of keeping improved deodorizing effect, by mixing royal jelly to a garlic, and freeze-drying the mixture or mixing previously freeze-dried garlic with royal jelly. CONSTITUTION:A raw garlic is skinned, and the calyx is removed to give a small scaly bulb, which is if necessary sliced in round slices. The resultant small scaly bulb or round slices are heated at 80-90 deg.C for tens of sec or some ten min and quenched by dipping in cool water. The blanched garlic is then finely pulverized to give a pasty garlic (A). <=90pts.wt. (solid weight) component (A) is then mixed with (B) >=10pts.wt. raw royal jelly, and the resultant mixture is freeze-dried or previously freeze-dried components (A) and (B) are mixed in the same proportion as described above to give the titled food consisting or dried mixture of white or yellowish powder or granule. The resultant food is directly filled in a gelatin capsule, etc. or mixed with oil, etc., and filled therein.
A denture cleansing composition for dissolution in water to form a cleansing bath with a initial pH of not more than 4.5. The composition contains at least one bleaching agent, at least one tartar removal agent, and at least one carbonate or bicarbonate. A combination of citric acid and malic acid as tartar removal agents results in increased tartar removal compared to citric acid or malic acid alone. The bleaching agent is an alkali metal or alkaline earth persulfate, perborate, percarbonate, or perphosphate. Preferably, the active agents are present as visually discrete particles.The composition is more stable than compositions having bisulfate as a tartar removal agent and avoids the unpleasant taste due to bisulfate. Potassium monopersulfate is an effective bleaching agent. Sodium bicarbonate and carbonate act as pH regulators and as effervescence agents to avoid gradient formation in the bath and to help remove particles from the dentures.
A method, computer program product, and system for generating flavor profile models are provided. An alpha flavor model is determined. An electrode signal is transmitted to a taste simulator based on the alpha flavor model. User feedback is received. A variance between the alpha flavor model and the user feedback is determined. The variance is compared to a predetermined threshold. In response to determining that the variance is greater than the predetermined threshold, a beta flavor model is generated.
Chronic sleep disruption (CSD), from insufficient or fragmented sleep and is an important risk factor for Alzheimer's disease (AD). Underlying mechanisms are not understood. CSD in mice results in degeneration of locus ceruleus neurons (LCn) and CA1 hippocampal neurons and increases hippocampal amyloid-β42 (Aβ42), entorhinal cortex (EC) tau phosphorylation (p-tau), and glial reactivity. LCn injury is increasingly implicated in AD pathogenesis. CSD increases NE turnover in LCn, and LCn norepinephrine (NE) metabolism activates asparagine endopeptidase (AEP), an enzyme known to cleave amyloid precursor protein (APP) and tau into neurotoxic fragments. We hypothesized that CSD would activate LCn AEP in an NE-dependent manner to induce LCn and hippocampal injury. Here, we studied LCn, hippocampal, and EC responses to CSD in mice deficient in NE [dopamine β-hydroxylase (Dbh)-/-] and control male and female mice, using a model of chronic fragmentation of sleep (CFS). Sleep was equally fragmented in Dbh -/- and control male and female mice, yet only Dbh -/- mice conferred resistance to CFS loss of LCn, LCn p-tau, and LCn AEP upregulation and activation as evidenced by an increase in AEP-cleaved APP and tau fragments. Absence of NE also prevented a CFS increase in hippocampal AEP-APP and Aβ42 but did not prevent CFS-increased AEP-tau and p-tau in the EC. Collectively, this work demonstrates AEP activation by CFS, establishes key roles for NE in both CFS degeneration of LCn neurons and CFS promotion of forebrain Aβ accumulation, and, thereby, identifies a key molecular link between CSD and specific AD neural injuries.
The present invention proposes a kind of ocean oligopeptides drug substance stable preparation technology, and it is comprised the technical steps that：1. the preparation of chitosan solution：Dissolve the chitosan in the acetic acid solution of 0.3%-0.5%, form the chitosan solution that mass volume ratio is 5-10mg/ml, it is overnight fully swelling；2. ocean oligopeptide solution is put into preparation：3. the preparation of shitosan-oligopeptides colloidal solution：By step, 2. obtained ocean oligopeptide solution is slowly dropped to step 1. in obtained chitosan solution, and is gradually stirred during dropwise addition；4. dry：By step 3. in shitosan-peptide colloidal solution carry out freeze-drying or spray drying, obtain ocean oligopeptides chitosan nano；5. pack：Dried ocean oligopeptides chitosan nano obtains final product ocean oligopeptides product by packaging.Additionally, the present invention also proposes a kind of by the ocean oligopeptides medicine prepared by above-mentioned preparation technology.